Adaptilens is proud to be featured in C&EN’s insightful article by Rowan Walrath, highlighting the impact of founder-led biotech companies. We’re honored by the recognition of our Founder and CEO, Dr. Liane Clamen, and grateful for the spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and the teams at Xontogeny, Perceptive Advisors, and Pillar VC.
Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.
Read MoreWe’re excited to share that Adaptilens has been nominated for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for this nomination. We are honored to be recognized with the other companies and breakthroughs of New England that are reshaping industries and driving the innovation economy forward. Read the full announcement here: https://lnkd.in/e548JKAk #NEVYsSurvivor #NEVCA #Innovation
Adaptilens is pleased to announce that our CEO, Dr. Liane Clamen, was invited to participate in a panel discussion on the "Future of Anterior Innovation" at the Ophthalmology Innovation Summit next month.
Follow our progress on
